Evidence map›Paper›PMID 32808106›Full record

ArticleAnnals of hematology2020

Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.

Henna-Riikka Junlén, Sandra Lockmer, Eva Kimby, Björn Engelbrekt Wahlin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Henna-Riikka JunlénUnit of Hematology, Department of Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden.
Sandra LockmerUnit of Hematology, Department of Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden.
Eva KimbyUnit of Hematology, Department of Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden.
Björn Engelbrekt WahlinUnit of Hematology, Department of Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden. bjorn.wahlin@sll.se.ORCID http://orcid.org/0000-0003-3566-8847
Karolinska University Hospital · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab monotherapy is widely used for follicular lymphoma. However, there are no established predictors for response or response duration. We analyzed the long-term prognostic relevance of pre-treatment absolute blood counts of lymphocytes with subsets and monocytes in 265 follicular lymphoma patients, uniformly treated with rituximab without chemotherapy, in two Nordic Lymphoma Group trials. There were 265 previously untreated, stage II-IV follicular lymphoma patients with a median follow-up of over 10 years. Absolute B cell counts ≥ median (0.09 × 10

Indexed as

B-LymphocytesLymphocyte CountAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDatasets as TopicFemaleFollow-Up StudiesHumansImmunosuppressive AgentsInterferon alpha-2Kaplan-Meier EstimateAntineoplastic AgentsImmunosuppressive AgentsInterferon alpha-2RituximabB cellFollicular lymphomaLymphocyteMonocyteRituximab

Identifiers

PMID32808106
PMCPMC7481163
OpenAlexW3062410865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.